News

Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. The company is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for

The performance of the novel biomarker, AGR2, will be further tested in an up-coming multi-centre, multi-national biomarker study planned by HealthLinx. Based on preliminary data, it is expected

Athersys also announced that it has been granted (the opposition period has cleared) EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, their isolation, expansion, and usage. The

AspenBio said that based on the interim analysis, the trial, currently with over 600 patients enrolled, will continue enrollment to approximately 800 patients with completion anticipated in March

Clarient said that the new test has been clinically validated to use in the sub-classification of patients with non-small cell lung cancer (NSCLC), which accounts for approximately 85%

The legislation, known as the Continuing Chemical Facilities Antiterrorism Security Act, was introduced today by Senator Susan Collins (R-ME), together with Senators Mark Pryor (D-AR), George Voinovich (R-OH),

The company expects to complete dosing in Q3, 2010, in preparation for filing a New Drug Application (NDA) with the FDA in Q4, 2010. In 2009, an open-label

The company informed that the packager is configured with an 18” x 24” seal system that utilises 25” pre-perforated centerfolded packaging material to create a bag around the

Fluidigm’s Access Array IFC, when used with an Illumina GA II sequencer, can capture up to 12kb of sequence data per sample, or 576kb per array. With upcoming